Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Abattis Bioceuticals Corp (ATT)

CBOE Canada
Currency in CAD
Disclaimer
0.08
0.00(0.00%)
Closed

ATT Comments

Untradeable for 6+ months on cse, Abattis or more likely bcse needs to do something and figure out if these guys are criminals or not. Do your jobs scum.
how much did you lose?
Just kidding !!! lol This stock is junk.
I just bought $160,000 worth, 2 months ago...what happened?
Halted for over 2 months, managers quitting left and right, audits not filed on time, do yourself a solid and never buy this stock.
Stocks been halted for a month. This company is a disgrace. I feel likre jake gyllenhaal in velvet buzz saw. "the respect and admiration I had for your work... Has completely evaporated!!"
Halted Feb 4th 8:00 am
Resumed yday Jan 21, halt related to nutrivida. Should be back to 8-8.5 today.
Halted right now, Jan 19 9:20am
Company has entered into a definitive share exchange agreement (the "Agreement") with 1157016 B.C. Ltd., dba NutriVida,
Going to see ten cents by the end of the week.
I'm in.....
Comfort Launch by Vergence Naturals Exceeds Expectations 12/11/2018 08:00 AM ET VANCOUVER, British Columbia, Dec 11, 2018 (GLOBE NEWSWIRE via COMTEX News Network) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to provide an update on the recent soft-launch of its cannabinoid-infused nutraceutical Comfort ("Comfort") through the Company's wholly-owned subsidiary, Vergence Naturals ("Vergence"), on Cyber-Monday, November 26, 2018. "The orders for Comfort were predominantly Canadian, with orders from the United States representing 42% of sales." "The extraordinary response to the soft-launch demonstrates the Company's ability to effectively execute a successful product launch as well as pointing out the significant demand for Comfort in both the Canadian and United States marketplaces as the cannabis industry continues to develop." President and CEO, Rob Abenante
I'm in......
Abattis Bioceuticals acquires genetic strain bank Nov. 23, 2018 1:16 PM • SA Editor Liz Kiesche "Abattis Bioceuticals (OTCQB:ATTBF) agrees to acquire 100% of Select Strains Inc, a company with a portfolio of more than 140 lab-tested craft cannabis strains, for about C$5M in common shares. Abattis will issue in 41.7M of its shares at a price of C$0.12 per share. " Well why not add that as well. Comfort release soon, and a type of craft selection portfolio for future seed or clone sales I'm guessing? Potential huge, haven't heard from from any of the big players regarding clone distribution or seed sales. That will be the next frontier in Canada recreational market. For the home grower, when they ban importing of seeds and restrict it to lps or approved seed/clone producers only. People don't even understand how much home growing there is in Canada, huge markets.
"2018 will end in a flurry of sales activity for Vergence Naturals surrounding the phytocannabinoid pain-reliever, Comfort! and Comfort Extra-Strength! Our relationship with Ingredient Identity will help us properly plan these product launches, while avoiding the legal mine-field associated with Canadian / US political animas,” added Dr. Minshew." Good news is great news.
this is the time. 10 days to go for new products.
Absolutely, been waiting for this news for ages. The release of Comfort will be huge.
Will be buying opportunity end of the day. People selling at 12 should be waiting but hey I'll pickup another 40k shares at least if it drops to there.
It's going to keep chipping up in small blocks, get in while it's lower than it will be end of Nov when Comfort and vape line is released. The time is now folks.
Looks to be 14 cents pre market, going to be another green day for abattis. Could see another 5-8% today.
Two days in a row gains. Going to steadily rise till the results come end of Nov, people should be getting on board now before then, you could be up 15% already. After Nov who knows but until then solid pickup.
This could easily be the biggest win of the year should Comfort and the vape line be a success. The risk/reward has never been greater. Not even a pump, this is a message from a higher power at this point. Buy.
battis Bioceuticals Offers Comfort to Those Suffering with Chronic Pain & Inflammation -- CFN Media 10/30/2018 09:00 AM ET SEATTLE, Oct 30, 2018 (GLOBE NEWSWIRE via COMTEX News Network) -- CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering the launch of Abattis Bioceuticals Corp.'s (CSE: ATT) (OTC: ATTBF) latest product innovation. "Comfort", a nutraceutical designed to alleviate chronic pain and inflammation, is the first in line of a dozen new products the company expects to launch over 36 months. According to a recent Institute of Medicine Report: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, stated, "Acute or chronic pain is a significant public health problem that costs society at least $560-$635 billion annually in North America alone.
This includes the total incremental cost of healthcare in North America due to pain ranging between $261 to $300 billion and $297-$336 billion due to lost productivity (based on days of work missed, hours of work lost, and lower wages). Additionally, the number of deaths associated with nonsteroidal anti-inflammatory drugs and opioids commonly used to treat those with chronic pain and inflammation has risen steadily." Overall, much more needs to be done to meet the challenges of pain and increase the widespread awareness of it. Abattis Bioceuticals took this goal to heart and set to work, analyzing not only the symptoms, but the physiology behind acute and chronic pain. The result is Comfort.
Goodbye ATT.
Ready for a run girls and boys
Strike deal with Oil of Olay, and lets get er done!
COMFORT Out in Cyber Monday . Lets get this to 0.40 cents
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.